Neumora Therapeutics, Inc. (NMRA) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

Medium Risk

Moderate dilution risk

Last updated: May 07, 2026

Risk Assessment Details

Potential Dilution: 16.02% of current shares

Recent Dilution: 14.56% (2 years)

Historical Dilution Factor: moderate recent dilution

Outstanding Shares

180M

Potential Supply

29M

Additional shares possible

Splits

None

Past 2 years

Summary

NMRA currently has 180M outstanding shares. with limited dilution risk as only 28.8M additional shares (16.0%) are authorized for issuance. The company has diluted shareholders by 14.56% over the past 2 years through share issuances.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding	Supply
May 07, 2026	10-Q filing \| 179.9M shares outstanding	180M	29M
Mar 30, 2026	10-K filing \| 182.0M shares outstanding	180M	29M
Nov 06, 2025	10-Q filing \| 161.8M shares outstanding	160M	29M
Aug 06, 2025	10-Q filing \| 161.7M shares outstanding	160M	29M
May 12, 2025	10-Q filing \| 161.5M shares outstanding	160M	29M
Mar 03, 2025	POS AM filing: Neumora Therapeutics, Inc. files a POS AM to offer and sell up to $600,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings.	160M	29M
Mar 03, 2025	10-K filing \| 159.4M shares outstanding	160M	29M
Nov 12, 2024	10-Q filing \| 159.6M shares outstanding	160M	29M
Aug 06, 2024	10-Q filing \| 159.0M shares outstanding	160M	29M
May 07, 2024	10-Q filing \| 157.9M shares outstanding	160M	29M
Mar 07, 2024	10-K filing \| 158.9M shares outstanding	160M	29M
Nov 01, 2023	10-Q filing \| 152.7M shares outstanding	150M	29M
Sep 11, 2023	S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. The company is offering 14,710,000 shares of common stock, with an option for underwriters to purchase an additional 2,206,500 shares. The company estimates net proceeds of approximately $227.5 million, or $262.3 million if the underwriters exercise their option. The intended use of proceeds is for clinical and preclinical development, research and development activities, working capital, and other general corporate purposes.	140M	29M
Aug 25, 2023	S-1 filing: This is an S-1 filing for an initial public offering of common stock.	1.1B	0

Back to NMRA Details